Clinical trial
Identification of Hepatic Lesions
NCT00307866 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00307866 |
|---|---|
| Title | Identification of Hepatic Lesions |
| Official title | A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatic Neoplasms |
| Intervention type | Procedure |
| Interventions | Resovist (BAY86-4884, SH U 555 A) |
| Enrollment | 218 |
| Start date | Apr 1, 2001 |
| Completion | May 1, 2003 |
| First posted | Mar 28, 2006 |
| Last update posted | May 18, 2009 |
| Countries | Italy |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: